Zoetis: 3 Key Takeaways for Long-Term Investors

Zoetis reported a 1% organic revenue decline in Q3 2026, pressured by lower veterinary clinic visits and generic competition in pet care. However, global livestock revenue grew 7% to $797 million, offsetting weakness. The company is deploying promotional strategies to defend market share in dermatology and relying on lifecycle innovations like Simparica Duo to extend core product franchises. Management expects continued macro headwinds into 2027 but maintains a long-term growth thesis centered on innovation and new therapeutic categories.